Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Take that Tresiba: Sanofi ups the insulin ante

This article was originally published in Scrip

Executive Summary

Sanofi's Lantus (insulin glargine) dramatically changed the insulin antidiabetics landscape and, with an estimated 80% share of the long-acting basal analogs market, the French firm is currently the clear leader in this segment. However, there are several threats to the blockbuster looming, which have prompted Sanofi to raise its game by developing a new suped-up version Lantus – insulin glargine U300. Datamonitor Healthcare's Sebastian Heinzmann explores the chances for this new arrival in an increasingly competitive market.

You may also be interested in...



A two horse race in the slow chase for safe obesity treatment

Has the pipe run dry for Novo Nordisk?

Lilly's dulaglutide: a blockbuster in the making

The safety and efficacy profile of Lilly's dulaglutide must measure up to Novo Nordisk's Victoza if it is to become a contender in the diabetes market, but as Datamonitor Healthcare analyst Dr Sebastian Heinzmann explains, it could do more than just that.

Topics

Related Companies

UsernamePublicRestriction

Register

SC021876

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel